Antifungal drugs in the treatment of systemic candidiosis: Susceptibility to antifungal drugs, point on drug resistance, pharmacological data;Utilisation des antifongiques dans le traitement des candidoses systémiques: Antifongigramme, point sur les résistances, données pharmacologiques

Annales Francaises d'Anesthesie et de Reanimation

Volumn 20, Issue 4, 2001, Pages 389-393

  Datry, A ^a   Thellier, M ^a   Traore B ^a   Alfa Cisse O ^a   Danis, M ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Amphotericin B; Antifungal drugs; Azole derivatives; Susceptibility to antifungal drugs

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; ECHINOCANDIN B; FLUCONAZOLE; FLUCYTOSINE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; ITRACONAZOLE; KETOCONAZOLE; PYRROLE DERIVATIVE; TRIAZOLE DERIVATIVE;

ANTIBIOTIC SENSITIVITY; CANDIDIASIS; CORRELATION FUNCTION; DISEASE ASSOCIATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; PHARYNGITIS; REVIEW;

EID: 0035011570     PISSN: 07507658     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0750-7658(01)00373-2     Document Type: Article

References (17)

1. Secular trends in the epidemiology of nosocomial fungal infections in the United States, to 1990 National Nosocomial Infections Surveillance System
2. Nosocomial infection rates in adult and pediatric intensive care units in the United States
3. Les liposomes, aspects pharmaceutiques, comportement in vivo et réalités cliniques
4. AmBisome (liposomal amphotericin B): A comparative review
5. Pharmacokinetics of liposomal amphotericin B (Ambisome) in critically ill patients
6. Lipid formulations of amphotericin B: Clinical efficacy and toxicities
7. Systemic antifungal agents. Drug interactions of clinical significance
8. Introduction to antifungal drugs
9. Overview of oral azol drugs as systemic antifungal therapy
10. Infection due to fluconazole-resistant Candida in patients with AIDS: Prevalence and microbiology
11. Development of interpretive breakpoints for antifungal susceptibility testing: Conceptual framework and analysis of in vivo-in vitro correlation data for fluconazole, itraconazole and Candida infections
12. Experimental hematogenous candidiasis caused by Candida krusei and Candida albicans: Species differences in pathogenicity
13. The changing face of nosocomial candidemia: Epidemiology, resistance, and drug therapy
14. A randomised, double-blind comparative trial evaluating the safety ofliposomal ampthotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia
15. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia
16. International conference for the development of a consensus on the management and prevention of severe candidal infections